Clopidogrel
Product Images NDC 64205-357

This is a figure presenting the effect of different proton pump inhibitors (PPIs) on the exposure to the active metabolite of clopidogrel bisulfate, a medication used to prevent blood clots. The figure shows the mean and 90% confidence interval of the change relative to clopidogrel bisulfate administered alone for each PPI. The PPIs evaluated were dexlansoprazole, lansoprazole, pantoprazole, and omeprazole at different doses. It is not possible to further analyze this information without additional context.*

The text describes a figure showing the cumulative event rate of cardiovascular death, myocardial infarction, and stroke in the CURE study. The figure shows two lines, one for the treatment group receiving "Clopidogrel Bisulfate (+ aspirin)" and one for the control group receiving "PLACERO (+ aspirin)". The x-axis shows the months of follow-up, while the y-axis shows the percentage of cumulative event rate. Other standard therapies were used as appropriate.*

This is a table from the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) study, showing the hazard ratio for patient baseline characteristics and concomitant medications/interventions on the study. The table includes the percent of events, the number of patients, and the hazard ratio with 95% confidence interval. There are subgroups based on baseline characteristics such as diagnosis, age, gender, and previous medical conditions. There are also categories for on-study medications or therapy such as heparin/LMAH or ACE inhibitors.*

This is a statistical report presenting cumulative event rates for death in a clinical trial named "COMMIT", with two groups of patients receiving either Placebo or Ciopidogrel treatments. The report shows that a higher proportion of patients who received Ciopidogrel treatment had died (75%) compared to those who received Placebo (6%). It also indicates a proportional risk before reduction (p=0.03) and mentions the day count since randomization for all treated patients who received aspirin.*

The figure 5 shows the cumulative event rates for the combined endpoint of re-infraction, stroke or death in the COMMIT study. The data compares the placebo group (10.1% with 2310 events) to the clopidogrel group (9.2% with 2121 events) over the first 28 days after randomization, resulting in a 9% proportional risk reduction (p = 0.002) for death, re-infarction or stroke before the first discharge.*

This is not-available.*

Figure 7 shows the effect of adding Clopidogrel Bisulfate to Aspirin in various subgroups in the COMMIT study. The table includes event percentages, odds ratios, and heterogeneity categorizations for each subgroup. The subgroups analyzed include Killip class, previous MI status, and infarct location. The table shows a decrease in events among patients who received both drugs in nearly all subgroups. The global heterogeneity test shows a significant result, indicating variation in the treatment effect across subgroups. The results suggest that the addition of Clopidogrel Bisulfate to Aspirin may be beneficial in reducing events in post-MI patients.*

The image shows data on fatal or non-fatal vascular events in the CAPRIE study. The study included aspirin and clopidogrel bisulfate treatment. The data is presented over the course of 36 months of follow-up, and a statistical analysis showed a significant difference between the two treatments (p=0.045).*